EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN

The article is dedicated to the use of immunomodulators in children, conditions, at which the prescription of this group of drugs is reasonable, action mechanism and also efficacy are given. In particular, the authors give their observation results for a group of HPV-infected children vaccinated by...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Ruleva, S. M. Kharit, E. P. Nacharova, I. V. Fridman
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2013-01-01
Series:Педиатрическая фармакология
Subjects:
Online Access:https://www.pedpharma.ru/jour/article/view/255
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849404660085948416
author A. A. Ruleva
S. M. Kharit
E. P. Nacharova
I. V. Fridman
author_facet A. A. Ruleva
S. M. Kharit
E. P. Nacharova
I. V. Fridman
author_sort A. A. Ruleva
collection DOAJ
description The article is dedicated to the use of immunomodulators in children, conditions, at which the prescription of this group of drugs is reasonable, action mechanism and also efficacy are given. In particular, the authors give their observation results for a group of HPV-infected children vaccinated by live vaccines (rubella and divalent measles-parotitis vaccine) together with pidotimod usage. No undesirable phenomena were registered in the postvaccinal period. Dynamics of immunological indicators did not change significantly. Seroconversion level of measles antibodies totaled 100% by the 30th observation day.
format Article
id doaj-art-9e2124ab8bab47e198cb126898581ff6
institution Kabale University
issn 1727-5776
2500-3089
language Russian
publishDate 2013-01-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-9e2124ab8bab47e198cb126898581ff62025-08-20T03:36:54ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892013-01-01101707310.15690/pf.v10i1.591255EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDRENA. A. Ruleva0S. M. Kharit1E. P. Nacharova2I. V. Fridman3Research institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian FederationResearch institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian FederationResearch institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian FederationResearch institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian FederationThe article is dedicated to the use of immunomodulators in children, conditions, at which the prescription of this group of drugs is reasonable, action mechanism and also efficacy are given. In particular, the authors give their observation results for a group of HPV-infected children vaccinated by live vaccines (rubella and divalent measles-parotitis vaccine) together with pidotimod usage. No undesirable phenomena were registered in the postvaccinal period. Dynamics of immunological indicators did not change significantly. Seroconversion level of measles antibodies totaled 100% by the 30th observation day.https://www.pedpharma.ru/jour/article/view/255biologic response modifier therapyhivlive vaccineschildren
spellingShingle A. A. Ruleva
S. M. Kharit
E. P. Nacharova
I. V. Fridman
EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
Педиатрическая фармакология
biologic response modifier therapy
hiv
live vaccines
children
title EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
title_full EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
title_fullStr EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
title_full_unstemmed EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
title_short EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
title_sort efficiency and safety of using pidotimod in vaccinated risk group children
topic biologic response modifier therapy
hiv
live vaccines
children
url https://www.pedpharma.ru/jour/article/view/255
work_keys_str_mv AT aaruleva efficiencyandsafetyofusingpidotimodinvaccinatedriskgroupchildren
AT smkharit efficiencyandsafetyofusingpidotimodinvaccinatedriskgroupchildren
AT epnacharova efficiencyandsafetyofusingpidotimodinvaccinatedriskgroupchildren
AT ivfridman efficiencyandsafetyofusingpidotimodinvaccinatedriskgroupchildren